Glasses that 'Talk' to Gene-Edited eyes: a new hope for blindness?
NCT ID NCT03326336
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a combination treatment for retinitis pigmentosa, a genetic disease that causes blindness. Ten adults receive a single injection of GS030 gene therapy into one eye, then use special glasses that send light signals to the treated retina. The main goal is to check safety, but researchers also measure any changes in vision. The study is still ongoing and not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GS030 gene therapy (injected into the eye) plus special glasses that stimulate the treated retina with light
- What this could lead to
- If it works, this could restore some vision in people with retinitis pigmentosa who have lost most sight.
- What could go wrong
- This is a very early, small trial (10 people) focused on safety, not proof of effectiveness. The gene therapy and glasses are experimental, and vision improvement is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SYNDROMIC RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier National d'Ophtalmologie (CHNP) des Quinze-Vingts
Paris, 75012, France
-
Moorfields Eye Hospital NHS Foundation Trust, 162 City Road
London, United Kingdom
-
UPMC Eye Center
Pittsburgh, Pennsylvania, 15213, United States